Although there are only a few large-scale clinical trials that have focused on the impact of SGLT2 inhibitors on renal protection, one of the SGLT2 inhibitors, empagliflozin, was reported to be associated with slower progression of kidney disease and lower rates of clinically relevant renal events in patients with type 2 diabetes mellitus [35]. Here, SLC5A2 is linked to diabetes mellitus.